A detailed history of Nuveen Asset Management, LLC transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 267,735 shares of CRBU stock, worth $404,279. This represents 0.0% of its overall portfolio holdings.

Number of Shares
267,735
Previous 267,735 -0.0%
Holding current value
$404,279
Previous $439,000 18.91%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$3.58 - $6.25 $66,928 - $116,843
18,695 Added 7.51%
267,735 $1.53 Million
Q3 2023

Nov 14, 2023

BUY
$4.08 - $8.14 $65,940 - $131,558
16,162 Added 6.94%
249,040 $1.19 Million
Q2 2023

Aug 14, 2023

SELL
$4.04 - $5.47 $242,747 - $328,670
-60,086 Reduced 20.51%
232,878 $989,000
Q1 2023

May 15, 2023

SELL
$4.3 - $7.78 $59,864 - $108,313
-13,922 Reduced 4.54%
292,964 $1.56 Million
Q4 2022

Feb 14, 2023

BUY
$5.57 - $11.01 $464,978 - $919,103
83,479 Added 37.37%
306,886 $1.93 Million
Q3 2022

Nov 14, 2022

SELL
$5.34 - $12.79 $167,991 - $402,360
-31,459 Reduced 12.34%
223,407 $2.36 Million
Q2 2022

Aug 15, 2022

BUY
$5.1 - $9.74 $319,698 - $610,561
62,686 Added 32.62%
254,866 $1.38 Million
Q1 2022

May 16, 2022

BUY
$8.42 - $15.32 $1.09 Million - $1.98 Million
129,399 Added 206.11%
192,180 $1.76 Million
Q4 2021

Feb 14, 2022

SELL
$14.59 - $23.26 $43,872 - $69,942
-3,007 Reduced 4.57%
62,781 $1.01 Million
Q3 2021

Nov 12, 2021

BUY
$15.75 - $30.29 $1.04 Million - $1.99 Million
65,788 New
65,788 $1.57 Million

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $91.9M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.